KATHERINE

NCT01772472 📎

Regimen

Experimental
T-DM1 (trastuzumab emtansine) 3.6 mg/kg IV every 3 weeks for 14 cycles.
Control
Trastuzumab 6 mg/kg IV every 3 weeks for 14 cycles.

Population

HER2-positive early breast cancer with residual invasive disease in breast or axillary nodes after neoadjuvant chemotherapy plus HER2-targeted therapy (non-pCR).

Key finding

KATHERINE established T-DM1 as the standard adjuvant escalation for HER2+ patients who did not achieve pCR after neoadjuvant therapy (NCCN category 1). First trial to demonstrate that residual-disease-driven escalation strategy improves outcomes in HER2+ early breast cancer.

Source: PMID 30516102

Timeline

  • Publication: 2019 Feb 14

Guideline citations

  • NCCN BREAST